Cytokines and chemokines in the vitreous fluid of eyes with uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 11, 2012, Pages 6748-6755

  Nagarkatti Gude, Nisha ^a   Bronkhorst, Inge H G ^a   van Duinen, Sjoerd G ^a   Luyten, Gregorius P M ^a   Jager, Martine J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; CHEMOKINE; CYTOKINE; EOTAXIN; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; RANTES; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHROMOSOME 3; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOXP3+ T LYMPHOCYTE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR VOLUME; UVEA MELANOMA; VITREOUS BODY;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MALE; MELANOMA; MIDDLE AGED; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY; UVEAL NEOPLASMS; VITREOUS BODY;

EID: 84867136912     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10123     Document Type: Article

References (49)

1. Virgili G, Gatta G, Ciccolallo L, et al. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114:2309-2315.
2. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005;18:75-84, viii.
3. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:956-961.
4. Jager MJ, Niederkorn JY, Ksander BR, eds. Uveal Melanoma: A Model for Exploring Fundamental Cancer Biology. London: Taylor & Francis; 2004.
5. Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, et al. Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. Ophthalmic Res. 2006;38:255-260.
6. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumorinfiltrating macrophages (CD68({thorn}) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42:1414-1421.
7. Durie FH, Campbell AM, Lee WR, Damato BE. Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sci. 1990;31:2106-2110.
8. de la Cruz PO Jr, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65:112-115.
9. Toivonen P, Makitie T, Kujala E, Kivela T. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Invest Ophthalmol Vis Sci. 2004;45:1-6.
10. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
11. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
12. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117: 1175-1183.
13. Lee CS, Jun IH, Kim TI, Byeon SH, Koh HJ, Lee SC. Expression of 12 cytokines in aqueous humour of uveal melanoma before and after combined Ruthenium-106 brachytherapy and transpupillary thermotherapy. Acta Ophthalmol. 2012;90:e314-e320.
14. Ly LV, Bronkhorst IH, van Beelen E, et al. Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. Invest Ophthalmol Vis Sci. 2010;51: 5445-5451.
15. Dunavoelgyi R, Funk M, Sacu S, et al. Intraocular activation of angiogenic and inflammatory pathways in uveal melanoma. Retina. 2012;32:1373-1384.
16. Bronkhorst IH, Ly LV, Jordanova ES, et al. Detection of M2macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci. 2011;52:643-650.
17. van Vlierberghe RL, Sandel MH, Prins FA, et al. Four-color staining combining fluorescence and brightfield microscopy for simultaneous immune cell phenotyping and localization in tumor tissue sections. Microsc Res Tech. 2005;67:15-21.
18. Bronkhorst IHG, Khanh Vu TH, Jordanova ES, Luyten GPM, van der Burg SH, Jager MJ. Different subsets of tumorinfiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci. 2012;53:5370-5378.
19. Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8{thorn} tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007;67:354-361.
20. Maat W, Jordanova ES, van Zelderen-Bhola SL, et al. The heterogeneous distribution of monosomy 3 in uveal melanomas: implications for prognostication based on fine-needle aspiration biopsies. Arch Pathol Lab Med. 2007;131:91-96.
21. Cools-Lartigue J, Marshall JC, Caissie AL, Saraiva VS, Burnier MN Jr. Secretion of interleukin-6 and prostaglandin E2 during uveal melanoma-monocyte in vitro interactions. Exp Eye Res. 2004;79:451-454.
22. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol. 2010;22:347-352.
23. Eikawa S, Ohue Y, Kitaoka K, et al. Enrichment of Foxp3{thorn} CD4 regulatory T cells in migrated T cells to IL-6and IL-8expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol. 2010;185:6734-6740.
24. Nakagawa T, Tsuruoka M, Ogura H, et al. IL-6 positively regulates Foxp3{thorn}CD8{thorn} T cells in vivo. Int Immunol. 2010;22: 129-139.
25. Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med. 2006;203:359-370.
26. Heller EA, Liu E, Tager AM, et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation. 2006;113:2301-2312.
27. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. 2003;100:2645-2650.
28. Feldmann M, Maini RN. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 1999;38(suppl 2);3-7.
29. Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D. Angiogenesis in rheumatoid arthritis. Histol Histopathol. 2006;21:557-566.
30. Weinreich DM, Elaraj DM, Puhlmann M, et al. Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer Res. 2003;63: 5957-5961.
31. Woodward JK, Elshaw SR, Murray AK, et al. Stimulation and inhibition of uveal melanoma invasion by HGF, GRO, IL-1alpha, and TGF-beta. Invest Ophthalmol Vis Sci. 2002;43:3144-3152.
32. Triozzi PL, Aldrich W, Singh A. Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma. Invest Ophthalmol Vis Sci. 2011;52:5529-5535.
33. Boyd SR, Tan D, Bunce C, et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol. 2002;86:448-452.
34. Missotten GS, Notting IC, Schlingemann RO, et al. Vascular endothelial growth factor A in eyes with uveal melanoma. Arch Ophthalmol. 2006;124:1428-1434.
35. Bronkhorst IHG, Jager MJ. Uveal melanoma: the inflammatory microenvironment. J Innate Immun. 2012;4:454-462.
36. Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, SchalijDelfos NE, Jager MJ. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:505-510.
37. van den Bosch T, van Beek JG, Vaarwater J, et al. Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci. 2012;53:2668-2674.
38. Bronkhorst IH, Maat W, Jordanova ES, et al. Effect of heterogeneous distribution of monosomy 3 on prognosis in uveal melanoma. Arch Pathol Lab Med. 2011;135:1042-1047.
39. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11:255-263.
40. Damato B, Coupland SE. A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye. 2009; 23:2152-2160; quiz 2161-2162.
41. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A metaanalysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992;110:245-250.
42. Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989-998.
43. Obiri NI, Husain SR, Debinski W, Puri RK. Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin Cancer Res. 1996;2:1743-1749.
44. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res. 1995;1:1253-1258.
45. Husain SR, Obiri NI, Gill P, et al. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res. 1997;3:151-156.
46. Kawakami K, Kawakami M, Joshi BH, Puri RK. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 2001;61:6194-6200.
47. Kawakami K, Kioi M, Liu Q, Kawakami M, Puri RK. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. J Immunother. 2005;28:193-202.
48. Yang H, Dithmar S, Grossniklaus HE. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells. Invest Ophthalmol Vis Sci. 2004;45:2056-2064.
49. Dithmar SA, Rusciano DA, Armstrong CA, Lynn MJ, Grossni-klaus HE. Depletion of NK cell activity results in growth of hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res. 1999;19:426-431.